<DOC>
	<DOCNO>NCT01634217</DOCNO>
	<brief_summary>This phase I single center dose escalation study extension best available dose determine tolerability inducible regulatory T cell ( iTregs ) give adult patient undergoing non-myeloablative HLA-identical sibling donor peripheral blood stem cell ( PBSC ) transplantation treatment high risk malignancy . Up 5 dose cohort test . Once tolerable dose determine iTregs , enrollment continue additional 10 patient use sirolimus/Mycophenolate mofetil ( MMF ) graft-versus-host disease ( GVHD ) prophylaxis gain safety information provide pilot data treatment setting .</brief_summary>
	<brief_title>Inducible Regulatory T Cells ( iTregs ) Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell Transplantation</brief_title>
	<detailed_description>Co-enrollment University Of Minnesota protocol MT2001-10 require transplantation accord protocol iTregs administer morning day 0 follow sooner 4 hour later PBSC transplantation .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<criteria>18 75 year age HLAidentical sibling donor One follow disease category : Acute myelogenous leukemia high risk CR1 ( evidence precede MDS , intermediate high risk cytogenetics , ≥ 2 cycle obtain CR , erythroblastic megakaryocytic leukemia ; CR2+ . All patient must CR defined hematological recovery ( ANC &gt; 0.5x 109/L ) , AND &lt; 5 % blast light microscopy within bone marrow cellularity ≥15 % . Acute lymphocytic leukemia high risk CR1 [ ( 9 ; 22 ) , ( 1:19 ) , ( 4 ; 11 ) MLL rearrangement ] &gt; 1cycle obtain CR ; CR2+ . All patient must CR defined hematological recovery ( ANC &gt; 0.5x 109/L ) , AND &lt; 5 % blast light microscopy within bone marrow cellularity ≥15 % . Chronic myelogenous leukemia type except blast crisis ( note treat blast crisis chronic phase eligible ) NonHodgkin lymphoma Hodgkin lymphoma demonstrate chemosensitive disease Myelodysplastic syndrome severe pancytopenia , lead either transfusion dependency increase risk infection Performance status : Karnofsky ≥ 60 % Adequate organ function within 28 day study enrollment define : Liver : SGOT SGPT &lt; 5.0 x ULN ; total bilirubin &lt; 3 x ULN Renal : serum creatinine &lt; 2.0 mg/dl glomerular filtration rate ( GFR ) &gt; 40 mL/min/1.73m2 . Patients creatinine &gt; 1.2 mg/dl history renal dysfunction must glomerular filtration rate ( GFR ) &gt; 40 mL/min/1.73m2 Albumin : &gt; 2.5 g/dL Cardiac : No decompensated CHF uncontrolled arrhythmia ; ejection fraction &gt; 35 % within 6 week prior study enrollment Pulmonary : No O2 requirement ; DLCO &gt; 30 % predict within 6 week prior study enrollment If recent mold infection ( e.g . aspergillus ) must minimum 30 day therapy responsive disease clear Infectious Disease Sexually active female child bear potential male must agree use effective contraception duration transplant period Voluntary write consent Pregnancy breast feed woman childbearing potential must negative pregnancy test within 28 day study enrollment . Prior myeloablative transplant within previous 3 month study enrollment . Evidence HIV infection know HIV positive serology . Active serious infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>